|
Joel Habener
Joel Habener is a Professor of Medicine at Harvard Medical School. Habener worked with Svetlana Mojsov on elucidating the role of incretin hormones such as Glucagon-like peptide-1 (GLP-1) and Glucagon-like peptide-2 (GLP-2). Habener received credit for the work on hormones when Mosjov was not credited. Habener was awarded the 2020 Warren Alpert Foundation Prize along with Daniel Drucker and Jens Juul Holst. He was elected to the National Academy of Sciences in 2020. In 2021 he was awarded the Canada Gairdner International Award. In 2023, he received the VinFuture Prize The VinFuture Prize is an annual international award that honors remarkable scientific breakthroughs and promotes innovations for mankind, with involvement from world-renowned scientists, policymakers, business leaders, and Prize holders. It is t .... References Harvard Medical School staff Medical researchers Members of the United States National Academy of Sciences Living people Year of birth missin ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Harvard Medical School
Harvard Medical School (HMS) is the graduate medical school of Harvard University and is located in the Longwood Medical Area of Boston, Massachusetts. Founded in 1782, HMS is one of the oldest medical schools in the United States and is consistently ranked first for research among medical schools by '' U.S. News & World Report''. Unlike most other leading medical schools, HMS does not operate in conjunction with a single hospital but is directly affiliated with several teaching hospitals in the Boston area. Affiliated teaching hospitals and research institutes include Dana–Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Boston Children's Hospital, McLean Hospital, Cambridge Health Alliance, The Baker Center for Children and Families, and Spaulding Rehabilitation Hospital. History Harvard Medical School was founded on September 19, 1782, after President Joseph Willard presented a report with ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Svetlana Mojsov
Svetlana Mojsov is a Macedonian American, ex- Yugoslavian-born chemist who is a research associate professor at Rockefeller University. Her research considers peptide synthesis. She discovered the glucagon-like peptide-1 and uncovered its role in glucose metabolism and the secretion of insulin. Her breakthroughs were transformed by Novo Nordisk into therapeutic agents against diabetes and obesity. Early life and education Mojsov was born in Skopje, Macedonia, ex Yugoslavia and did her undergraduate degree in physical chemistry in Belgrade. She joined the graduate program at the Rockefeller University in 1972, where she worked alongside Robert Bruce Merrifield (1984 Nobel Prize in Chemistry) on the synthesis of peptides. Specifically, Mojsov focused on the synthesis of glucagon, which is released by the pancreas. At the time it was proposed that glucagon might help to treat Type 2 diabetes. Research and career In the 1980s, Mojsov moved to the Massachusetts General Hospital, ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Incretin
Incretins are a group of metabolic hormones that stimulate a decrease in blood glucose levels. Incretins are released after eating and augment the secretion of insulin released from pancreatic beta cells of the islets of Langerhans by a blood-glucose–dependent mechanism. Some incretins (GLP-1) also inhibit glucagon release from the alpha cells of the islets of Langerhans. In addition, they slow the rate of absorption of nutrients into the blood stream by reducing gastric emptying and may directly reduce food intake. The two main candidate molecules that fulfill criteria for an incretin are the intestinal peptides glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP, also known as: glucose-dependent insulinotropic polypeptide). Both GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4). Both GLP-1 and GIP are members of the glucagon peptide superfamily. Medical uses Medications based on incretins are used in the treatment of diabe ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Glucagon-like Peptide-1
Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from the tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by intestinal enteroendocrine L-cells and certain neurons within the nucleus of the solitary tract in the brainstem upon food consumption. The initial product GLP-1 (1–37) is susceptible to amidation and proteolytic cleavage, which gives rise to the two truncated and equipotent biologically active forms, GLP-1 (7–36) amide and GLP-1 (7–37). Active GLP-1 protein secondary structure includes two α-helices from amino acid position 13–20 and 24–35 separated by a linker region. Alongside glucose-dependent insulinotropic peptide (GIP), GLP-1 is an incretin; thus, it has the ability to decrease blood sugar levels in a glucose-dependent manner by enhancing the secretion of insulin. Beside the insulinotropic effects, GLP-1 has been associated with numerous regulatory and protective e ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |